- Home
- »
- Biotechnology
- »
-
Competitive Landscape Of Top CRISPR Technology CompaniesGVR Report cover
Competitive Landscape Of Top CRISPR Technology Companies
Report Overview
Our healthcare portfolio has been developing since our inception in 2014, wherein we have tracked numerous sub-domains and their R&D activities. We have actively been tracking genomics and genetic engineering space and have seen the evolution of these players over time. To help understand and highlight their development journey, we have made this special study that focuses on the top CRISPR technology companies.
CRISPR technology is being rapidly adopted in various domains of the life sciences industry due to its precision and efficiency in gene editing which has revolutionized research, allowing scientists to make highly targeted modifications with minimal off-target effects. The technology is relatively cost-effective compared to other gene editing methods such as Transcription Activator-Like Effector Nucleases (TALENs) or Zinc Finger Nucleases (ZFNs), making it accessible to a broader range of researchers and institutions. Furthermore, the growing demand for personalized medicine and innovative treatments for genetic disorders has sparked interest in CRISPR’s potential. As advancements in genomics and genetic engineering continue, the demand for sophisticated gene editing techniques like CRISPR technology is anticipated to grow rapidly.
Market Share Analysis for Top CRISPR Technology Product/Service Providers
The CRISPR technology industry features a diverse range of companies, from major industry leaders to innovative startups, each providing an array of products and services. As part of the research process, we have identified the key players operating in this market based on several parameters such as revenues, product portfolio, supply chain efficiency, and strategic initiatives, among others. We determined and analyzed the regional revenues of the key market players from annual reports and investor presentations and further identified the relevant business segments of these companies. We also performed exhaustive product mapping and estimated the product-specific revenues commanded by these players to perform a market share analysis.
During this process, we also conducted exhaustive secondary research through various data sources including research publications, white papers, press releases, and other authentic data sources to understand the key strategies adopted by these companies. Furthermore, we conducted primary interviews from both the supply side and demand side of the market to obtain insights and validate our findings. Besides this, we referred to our large repository of market reports for various sectors and subsectors within the biotechnology industry. The data obtained from primary interviews, secondary research, and our in-house database was triangulated and processed to derive the market share of key companies. The dataset was further validated by industry experts through telephonic interviews and questionnaire-based surveys.
Competitive Landscape: Top CRISPR Technology Companies Report Coverage
The CRISPR technology market is highly competitive, with leading companies like Thermo Fisher Scientific, Inc. and Merck KGaA offering a wide range of products and services. Furthermore, as companies like Cellecta, Origene Technologies, and other emerging innovators continue to advance in this field, competition within the industry is expected to increase further.
The report analyses the competitive landscape in this industry based on parameters mentioned below:
Competitive Landscape: Top CIRSPR Technology Companies Overview
Market Outlook
Company Categorization
Pipeline Analysis
Company Market Share/ Position Analysis
List of Key Companies by Region
Funding & Investment Scenario
Regulatory Framework
Company Overview
Product/Service Benchmarking
Financial Performance
Recent Strategic Initiatives
SWOT Analysis
Pipeline Analysis for CRISPR-based Clinical Trials
The recent regulatory approval of Casgevy (exagamglogene autotemcel), a therapy for sickle cell disease and transfusion-dependent β-thalassemia, in November 2023 by UK’s regulatory authority has demonstrated CRISPR’s utility in commercial applications. This has led to a heightened interest in the development of novel CRISPR-based therapeutic and diagnostic solutions. The following figure shows the percentage of clinical trials investigating CRISPR-based solutions, by disease area, as of Q4 2023.

Despite the growing excitement however, the field faces significant challenges. Due to the economic downturn in the biotechnology industry following the COVID-19 pandemic, investors now demand quicker returns. This pressure is leading companies to focus on advancing clinical trials and rapidly bringing products to market. The financial pressure, coupled with the high costs of clinical trials, has caused companies to narrow their focus to the most advanced products instead of expanding their research or developing new treatments. This factor may limit the number of new trials being introduced in the CRISPR technology field.
Competitive Analysis: Thermo Fisher Scientific, Inc.
Company Overview:
-
Headquarter: Massachusetts, U.S.
-
Establishment Year: 1956
-
Employee Strength (2023): 122,000
-
Business Overview: Thermo Fisher Scientific, Inc. is a key player in the life sciences and biotechnology sectors, recognized for its comprehensive range of products and services that support scientific research and clinical applications. The company specializes in areas such as molecular biology, cell culture, genomics, and offers cutting-edge tools, including reagents and instrumentation. It caters to a wide spectrum of end-users, from academic researchers to pharmaceutical companies. Thermo Fisher Scientific's CRISPR portfolio includes various tools and reagents, such as CRISPR-Cas9 nucleases, guide RNA libraries, and cell engineering services, designed to facilitate precise gene editing across various applications. The company’s extensive portfolio has solidified its position as a key player in the CRISPR technology industry.
SWOT Analysis:
SWOT Analysis - Thermo Fisher Scientific, Inc.
Strengths
Weaknesses
- A broad portfolio of CRISPR genome-editing products and services, including guide RNAs and reagents that are essential for precise gene editing.
- A strong brand reputation and a broad customer base provides the company a competitive edge.
- Thermo Fisher's CRISPR products are heavily reliant on established markets in North America and Europe, potentially limiting growth in less-developed regions.
- Although the company offers a broad range of CRISPR tools, the customization options may not be as flexible as those provided by specialized competitors.
Opportunities
Threats
- With the growing interest in CRISPR-based therapies, the company can expand its offerings into clinical and therapeutic applications.
- Strategic partnerships with biotech firms and research institutions could accelerate the development and adoption of new CRISPR applications, enhancing market share.
- Challenges related to ethical considerations of gene editing techniques can restrict the company’s growth.
- Risks associated with patent disputes or intellectual property challenges in the highly competitive CRISPR field could threaten the company’s growth.
Financial Performance:
Key Financials (Thermo Fisher Scientific, Inc.)
2023 (USD million)
2022 (USD million)
2021 (USD million)
Revenue
42,857
44,915
39,211
Operating Income/Loss
6,859
8,393
10,028
EBIT/EBITA
6,298
7,835
8,841
Net Income/Loss
5,955
6,960
7,728
List of top 15 CRISPR technology product/service providers:
-
Thermo Fisher Scientific
-
Horizon Discovery
-
Merck KGaA
-
Synthego
-
Danaher
-
Agilent Technologies
-
GenScript
-
Takara Bio
-
Origene Technologies
-
New England Biolabs (NEB)
-
Cellecta
-
Qiagen
-
Santa Cruz Biotechnology
-
Addgene
-
OZ Biosciences
List of top 15 CRISPR technology therapeutics companies:
-
CRISPR Therapeutics
-
Editas Medicine
-
Intellia Therapeutics
-
Caribou Biosciences
-
Beam Therapeutics
-
Graphite Bio
-
Precision BioSciences
-
Verve Therapeutics
-
Poseida Therapeutics
-
EdiGene
-
Passage Bio
-
Allogene Therapeutics
-
HuidaGene Therapeutics
-
Prime Medicine
-
Excision Biotherapeutics
-
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.